Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470925 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00470925 is a Phase 1 study that was terminated before completion, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 30 participants.
The verdict
NCT00470925, a Phase 1 study, was terminated before completion, sponsored by Institute for Neurodegenerative Disorders.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The overall purpose of this project is to evaluate the effect of sertraline administration on the binding of 123-I mZINT in 10 healthy subjects. All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging (MNI) in New Haven, CT.
Interventions
- DRUG 123-I MZINT injection and SPECT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470925
The ClinicalTrials.gov registry entry for NCT00470925 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 123-I MZINT injection and SPECT imaging is the first listed.
NCT00470925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470925 about?
NCT00470925 is a clinical study titled "Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects". The overall purpose of this project is to evaluate the effect of sertraline administration on the binding of 123-I mZINT in 10 healthy subjects. All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging (MNI) in New Haven, CT.
What is the current status of trial NCT00470925?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-05. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00470925?
The interventions under investigation include: 123-I MZINT injection and SPECT imaging (DRUG).
Who is sponsoring clinical trial NCT00470925?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.